Industry transition Opportunity to engage Abcam post-merger, leveraging Expedeon’s integration into Abcam to position complementary antibodies, assay solutions, and related research tools aligned with Abcam’s expanded capabilities.

Sustainability tie Highlight potential for sustainable lab workflows and quality-controlled ELISA platforms like SimpleStep Ignite, aligning with Abcam’s product innovations to appeal to buyers seeking reliable, efficient assay solutions.

AI and analytics Leverage existing tech stack use (AWS, Oracle Marketing, Microsoft Clarity) to propose data-driven purchasing decisions, lab analytics support, and targeted digital marketing collaborations that accelerate adoption of Expedeon/Abcam offerings.

Leadership transitions Monitor leadership changes at Abcam for strategic purchasing impact; align outreach with new president and executive priorities to time communications around supply chain reliability and product launches.

Cross-sell potential Capitalize on Abcam’s expanded portfolio by proposing integration of Expedeon products with Abcam’s validated antibodies and assay solutions, including Markergene acquisition synergies, to create bundled offerings for researchers.